ND0612 ongoing clinical trials

If you or a loved one are being treated for advanced Parkinson’s disease, consider ND0612 clinical studies

ND0612-006

A parallel-group, randomized clinical study in 36 patients with advanced PD who are treated with 4 or more doses of levodopa per day, and have at least 2.5 hours of “OFF” time a day. The objective is to evaluate the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of high dose ND0612 in patients with advanced PD over a 4 week period. The primary end point will be the mean change in the daily “OFF” time.
For more details press here

ND0612-012 – BeyoND

A phase II, open label, clinical study in 120 patients with advanced PD who are treated with 4 or more doses of levodopa per day, and have at least 2 hours of “OFF” time a day. The objective is to evaluate the long term safety and tolerability of subcutaneous infusion of ND0612 in patients with advanced PD over a 12-month period. The primary end point will be the long term systemic and local safety and tolerability of ND0612 infusion.
For more details press here

What is ND0612 ? Risks related to ND0612 clinical studies